Solvay and Wyeth collaborate for discovery of anti-psychotics with novel mechanisms
Expansion of existing neuroscience agreement
Solvay Pharmaceuticals and Wyeth Pharmaceuticals announced that they are expanding their existing neuroscience co-development, and co-commercialization agreement to include research in neuroscience. The neuroscience co-development and co-commercialisation partnership already announced in April 2004 between Solvay and Wyeth has resulted in a New Drug Application for bifeprunox for the treatment of patients with schizophrenia, submitted in October 2006 to the U.S. food and Drug Administration and filed by them in December. Meanwhile development continues on two other early phase neuroscience projects SLV313 and SLV314, which were part of that agreement.
Under the new agreement the parties will collaborate in a joint discovery effort targeting the identification of small molecules with the potential to be used as anti-psychotic medications. Any compounds discovered under this research collaboration will be co-owned and co-patented by Solvay and Wyeth and could be selected for co-development and co-commercialization by both companies.
The parties will initially contribute several molecules each into this collaboration, and thereafter dedicate equal resources to the research efforts. There are no signing fees or milestone payments associated with this agreement.
Other news from the department business & finance
